Promising results from first-in-humans study of a novel PET
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well-tolerated and safe.

The radiopharmaceutical is a 68Ga-labeled Siglec-9 peptide. The study also included the imaging of a patient with early rheumatoid arthritis. The inflamed joints were clearly visible in the PET images, and the radiopharmaceutical seems to effectively target inflamed tissue.

"The dose of the radiopharmaceutical used in PET imaging is thousands of times lower when compared with the regular drugs. Studies with new radiopharmaceuticals are therefore safer than the usual drug research studies," explain the researchers.

"This study is unique and has a long, innovative history at the University of Turku. Now, it has been proven that the new radiopharmaceutical works in humans," says Academician of Science, Professor Sirpa Jalkanen.

Journal of Nuclear Medicine
Source: https://jnm.snmjournals.org/content/62/4/577
Like
Comment
Share